Abstract
CD30, originally identified as a cell-surface marker of Reed-Sternberg and Hodgkin cells of classical Hodgkin lymphoma, is also expressed by several types of non-Hodgkin lymphoma, including a subset of diffuse large B-cell lymphoma (DLBCL). However, the prognostic and biological importance of CD30 expression in DLBCL is unknown. Here we report that CD30 expression is a favorable prognostic factor in a cohort of 903 de novo DLBCL patients. CD30 was expressed in ∼14% of DLBCL patients. Patients with CD30(+) DLBCL had superior 5-year overall survival (CD30(+), 79% vs CD30(-), 59%; P = .001) and progression-free survival (P = .003). The favorable outcome of CD30 expression was maintained in both the germinal center B-cell and activated B-cell subtypes. Gene expression profiling revealed the upregulation of genes encoding negative regulators of nuclear factor κB activation and lymphocyte survival, and downregulation of genes encoding B-cell receptor signaling and proliferation, as well as prominent cytokine and stromal signatures in CD30(+) DLBCL patients, suggesting a distinct molecular basis for its favorable outcome. Given the superior prognostic value, unique gene expression signature, and significant value of CD30 as a therapeutic target for brentuximab vedotin in ongoing successful clinical trials, it seems appropriate to consider CD30(+) DLBCL as a distinct subgroup of DLBCL.
Original language | English |
---|---|
Journal | Blood |
Volume | 121 |
Issue number | 14 |
Pages (from-to) | 2715-24 |
Number of pages | 10 |
ISSN | 0006-4971 |
DOIs | |
Publication status | Published - 4 Apr 2013 |
Keywords
- Antibodies, Monoclonal, Murine-Derived
- Antigens, CD30
- Antineoplastic Agents
- Antineoplastic Combined Chemotherapy Protocols
- Cyclophosphamide
- Disease-Free Survival
- Doxorubicin
- Female
- Follow-Up Studies
- Gene Expression Regulation, Neoplastic
- Humans
- Lymphoma, Large B-Cell, Diffuse
- Male
- Middle Aged
- Multivariate Analysis
- Prednisone
- Prognosis
- Survival Analysis
- Transcriptome
- Treatment Outcome
- Vincristine